major challenge in SCLC compared with non–small cell lung cancer has been the lack of targetable driver mutations. TP53 and RB1 alterations are nearly ubiquitous in SCLC, noted Dr. Ganti. However, other mutations like CREBBP , TP73 , and NOTCH1
Search Results
Updates in the Management of Small Cell Lung Cancer
Presented by: Apar Kishor Ganti
Lung Cancer Screening, Version 1.2015
Douglas E. Wood, Ella Kazerooni, Scott L. Baum, Mark T. Dransfield, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Ann N.C. Leung, Samir S. Makani, Pierre P. Massion, Bryan F. Meyers, Gregory A. Otterson, Kimberly Peairs, Sudhakar Pipavath, Christie Pratt-Pozo, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Peter B. Sachs, Matthew B. Schabath, Lecia V. Sequist, Betty C. Tong, William D. Travis, Stephen C. Yang, Kristina M. Gregory, and Miranda Hughes
, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Lung Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Lung Cancer Screening
What, When, and How of Biomarker Testing in Non–Small Cell Lung Cancer
Gregory L. Riely
Biomarker testing for patients with non–small cell lung cancer [NSCLC] is critically important, but it can be complicated,” explained Gregory L. Riely, MD, Vice Chair, Clinical Research, Department of Medicine, Memorial Sloan Kettering Cancer
Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer
Eric M. Lander, Xuanyi Li, Li-Ching Huang, Amanda S. Cass, Wade T. Iams, Emily A. Skotte, Jennifer G. Whisenant, Robert A. Ramirez, Sally J. York, Travis J. Osterman, Jennifer A. Lewis, Christine M. Lovly, Yu Shyr, and Leora Horn
, oncologist advice to consider hospice, readmission due to previous premature hospital discharge, and failure of timely outpatient follow-up. 11 – 13 More than half of patients with lung cancer experience unplanned admissions following their diagnosis, and in
Management of Patients With Lung Cancer and Poor Performance Status
Ajeet Gajra, Alissa S. Marr, and Apar Kishor Ganti
/print certificate. Release date: July 8, 2014; Expiration date: July 8, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Describe the available evidence on the treatment of patients with lung cancer who are
Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations
Sheena Bhalla, Vijaya Natchimuthu, Jessica L. Lee, Urooj Wahid, Hong Zhu, Noel O. Santini, Travis Browning, Heidi A. Hamann, David H. Johnson, Hsienchang Chiu, Simon J. Craddock Lee, and David E. Gerber
Background Despite considerable treatment advances over the last decade, lung cancer remains the leading cause of cancer death in the United States. 1 More than three-quarters of individuals present with advanced disease, contributing to
Non–Small Cell Lung Cancer, Version 2.2013
David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr, Stefan C. Grant, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Douglas E. Wood, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
: Integrate into professional practice the updates to NCCN Guidelines for NSCLC. Describe the rationale behind the decision-making process for developing the NCCN Guidelines for NSCLC. NCCN Guidelines Insights : Non-Small Cell Lung Cancer
Immunotherapies for Lung Cancer
Matthew A. Gubens
Matthew A. Gubens, MD, MS, Assistant Clinical Professor of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discussed the past, present, and future of immunotherapies for non–small cell lung cancer (NSCLC) at the NCCN 22nd Annual
Genomic Testing in Lung Cancer: Past, Present, and Future
Céline Mascaux, Ming-Sound Tsao, and Fred R. Hirsch
toxicities. Subsequent to the application of high-throughput genomic sequencing to lung cancer, many mutations had been identified in different histologic subtypes. Some of these mutations or other molecular alterations (eg, chromosomic rearrangements
Non–Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology
Gregory J. Riely, Douglas E. Wood, David S. Ettinger, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Aakash P. Desai, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aditya Juloori, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Dawn Owen, Dwight H. Owen, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Jonathan Riess, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Lisa Hang
Overview Lung cancer is the leading cause of cancer-related deaths in the United States. 1 , 2 In 2024, an estimated 234,580 new cases (116,310 in males and 118,270 in females) of lung and bronchial cancer will be diagnosed, and 125
